Dr. Jessica L. Heath
Claim this profileUniversity of Vermont and State Agricultural College
About Jessica L. Heath
Education:
PhD in Plant Biology from the University of Vermont and State Agricultural College, 2015.
Experience:
Conducted postdoctoral research at the University of California, Davis, with a focus on plant genetics and genomics.
Currently a Research Scientist at the Donald Danforth Plant Science Center, specializing in crop improvement and plant biotechnology.
Area of expertise
Cancer
Jessica L. Heath has run 17 trials for Cancer. Some of their research focus areas include:
Neuroblastoma
Jessica L. Heath has run 14 trials for Neuroblastoma. Some of their research focus areas include:
Affiliated Hospitals
University Of Vermont And State Agricultural College
Clinical Trials Jessica L. Heath is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting
2 awards
Phase 3
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting
2 awards
Phase 3
More about Jessica L. Heath
Clinical Trial Related
8 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 13 Active Clinical Trials
Treatments Jessica L. Heath has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Radiation Therapy
- Doxorubicin Hydrochloride
- Laboratory Biomarker Analysis
Breakdown of trials Jessica L. Heath has run
Cancer
Neuroblastoma
Brain Tumor
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jessica L. Heath specialize in?
Jessica L. Heath focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Jessica L. Heath currently recruiting for clinical trials?
Yes, Jessica L. Heath is currently recruiting for 12 clinical trials in Burlington Vermont. If you're interested in participating, you should apply.
Are there any treatments that Jessica L. Heath has studied deeply?
Yes, Jessica L. Heath has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Jessica L. Heath?
Apply for one of the trials that Jessica L. Heath is conducting.
What is the office address of Jessica L. Heath?
The office of Jessica L. Heath is located at: University of Vermont and State Agricultural College, Burlington, Vermont 05405 United States. This is the address for their practice at the University of Vermont and State Agricultural College.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.